CD161 receptor – a novel target for immunotherapy in diffuse gliomas

Written by Louis Gautier, Future Science Group

CD161 receptor

Dana-Farber researchers show that the CD161 receptor is more abundant on the surface of gliomas than PD-1 and could be a better target for immunotherapy. Recent in vitro research from the Dana-Farber Cancer Institute (MA, USA) has shed light on a potential new target for immune checkpoint inhibitors in diffuse gliomas. The inhibitory receptor, CD161, weakens the T-cell response against tumor cells and is more abundant in glioma cells than PD-1. Brain tumors are of the most aggressive forms of cancer and have so-far been particularly resistant to immunotherapy. It is understood that T cells can infiltrate glioma cells, but...

To view this content, please register now for access

It's completely free